TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT04794322

Intervention type: DIAGNOSTIC_TEST
Intervention: Uterine lavage, or a wash of the womb
Description: Uterine lavage is performed during surgery using a flexible, 3-way balloon tipped catheter. The catheter is inserted through the cervix, the balloon expanded and the uterine cavity lavaged using 10 cc of sterile saline which is collected, processed and stored for later analysis.

Intervention type: DIAGNOSTIC_TEST
Intervention: Uterine lavage, or a wash of the womb
Description: Uterine lavage is performed during surgery using a flexible, 3-way balloon tipped catheter. The catheter is inserted through the cervix, the balloon expanded and the uterine cavity lavaged using 10 cc of sterile saline which is collected, processed and stored for later analysis.

Intervention type: DIAGNOSTIC_TEST
Intervention: Blood sample
Description: Participants undergo two blood draws (one required, one optional) up to 31 days before surgery

Intervention type: DIAGNOSTIC_TEST
Intervention: Blood sample
Description: Participants undergo two blood draws (one required, one optional) up to 31 days before surgery

Intervention type: DIAGNOSTIC_TEST
Intervention: Pap smear
Description: Participants undergo a standard Papanicolaou smear to collect cells and fluid from the cervix.

Intervention type: DIAGNOSTIC_TEST
Intervention: Pap smear
Description: Participants undergo a standard Papanicolaou smear to collect cells and fluid from the cervix.
Study: NCT01454544

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: AIT Tablet
Description: 1 tablet per day in 12 months

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: AIT Tablet
Description: 1 tablet per day in 12 months

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: AIT Tablet
Description: 1 tablet per day in 12 months
Study: NCT04031131

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Instillagel
Description: Topical Anaesthetic Gel (Instillagel) licensed for rectal administration.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: KY Gel
Description: Lubricant Gel

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: KY Gel
Description: Lubricant Gel
Study: NCT05859841

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Music listening
Description: Music listening under instruction by music therapist, min 3 hours daily

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Control
Description: Standard treatment, care and rehabilitation
Study: NCT00096265

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: 3-Dimensional Conformal Radiation Therapy
Description: Patients undergo radiation therapy once daily for approximately 3 weeks

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: 3-Dimensional Conformal Radiation Therapy
Description: Patients undergo radiation therapy once daily for approximately 3 weeks

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: 3-Dimensional Conformal Radiation Therapy
Description: Patients undergo radiation therapy once daily for approximately 3 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Erlotinib Hydrochloride
Description: Given orally

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Stereotactic Radiosurgery
Description: Patients undergo surgery after radiation therapy

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Stereotactic Radiosurgery
Description: Patients undergo surgery after radiation therapy

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Stereotactic Radiosurgery
Description: Patients undergo surgery after radiation therapy

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Temozolomide
Description: Given orally
Study: NCT04043884

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: sEmg biofeedback training
Description: Volunteers will perform scapular strengthening and stabilization exercises added to sEMG biofeedback in the upper trapezius (TS), Trapezius (TM), Lower Trapezius (TI), and Serratil Anterior (AS) muscles in real time displayed in a Computer screen.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Strength training
Description: The volunteers will perform a strengthening protocol with elbow flexion exercises, medial and lateral shoulder rotation, scapular retraction and push up plus.
Study: NCT01572090

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Lifestyle Changes
Description: Hypocaloric diet providing a 1000 kcal/d deficit from total energy expenditure assessed by indirect calorimetry and physical activity determination.~Dietetic and physical activity counselling with a dietitian.
Study: NCT03750097

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Comfortable walking velocity (CWV)
Description: Walking for 250 Steps with self-selected comfortable walking velocity while wearing the two accelerometers (Polar M600 and ActiGraph wGT3X-BT)

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Slow walking velocity (SWV: CWV - 20%)
Description: Walking for 250 Steps with slow walking velocity while wearing the two accelerometers (Polar M600 and ActiGraph wGT3X-BT). Slow walking consists of walking with 20% slower than the self-selected comfortable walking velocity by following a researcher who controls the walking velocity with a measuring wheel.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Fast walking velocity (FWV: CWV + 20%)
Description: Walking for 250 Steps with fast walking velocity while wearing the two accelerometers (Polar M600 and ActiGraph wGT3X-BT). Fast walking consists of walking with 20% faster than the self-selected comfortable walking velocity by following a researcher who controls the walking velocity with a measuring wheel.
Study: NCT02555111

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Xarelto
Description: 15mg/day oral administration during 2 to 4 years (based on the recruitment date).
Study: NCT01944267

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Apically positioned flap
Description: Standard TUSDM Periodontology Clinic procedures will be followed. Local anesthesia will be achieved. Center of implant fixtures will be located. Crestal incision thru the center of implant fixture will be made. Implant fixture will be uncovered and healing abutment/s will be inserted. Horizontal incision at approximately 0.5mm coronal to buccalmucogingival junction will be made 1 tooth mesial to 1 tooth distal to the treating area.~No vertical incision will be made Gingiva coronal to horizontal incision will remain intact Partial thickness flap will be prepared and displaced apically approximately 7mm from the horizontal incision and secured with sutures.~Prepared surgical area will be measured apico-coronally and mesio-distally.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Free Gingival Graft
Description: Standard Clinic procedures followed. Local anesthesia achieved. Center of implant fixtures located. Crestal incision thru center of fixture will be made.~Implant fixture uncovered and healing abutment/s inserted. Horizontal incision at approx 0.5mm coronal to buccalmucogingival junction will be made 1 tooth mesial to 1 tooth distal to the treating area.~No vertical incision made. Gingiva coronal to horizontal incision remains intact.~Partial thickness flap prepared and displaced apically approximately 7mm from horizontal incision; secured with sutures. Prepared recipient bed measured apico-coronally and mesio-distally. Masticatory mucosa from palate of treating side (Right or Left) harvested according to size measured from recipient bed with width of approximately 5mm at line of measurement. Harvested graft material will be transplanted on recipient bed, lined with initial horizontal incision line with sutures

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: apically positioned flap with Mucograft
Description: Standard TUSDM Periodontology Clinic procedures followed. Local anesthesia achieved.~Center of implant fixtures will be located. Crestal incision thru the center of implant fixture will be made. Implant fixture will be uncovered and healing abutment/s will be inserted. Horizontal incision at approximately 0.5mm coronal to buccalmucogingival junction will be made 1 tooth mesial to 1 tooth distal to the treating area.~No vertical incision will be made. Gingiva coronal to horizontal incision will remain intact. Partial thickness flap will be prepared and displaced apically approximately 7mm from the horizontal incision and secured with sutures.~Prepared recipient bed will be measured apico-coronally and mesio-distally. Mucograft material will be prepared according to the manufacturer's instruction and trimmed as the size measured from the recipient and be placed and secured on the recipient bed with sutures.
Study: NCT04135820

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BPI-7711
Description: BPI-7711 180 mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BPI-7711
Description: BPI-7711 180 mg
Study: NCT02359474

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Trabectedin

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trabectedin

Intervention type: GENETIC
Group type: ACTIVE_COMPARATOR
Intervention: DNA double-strand breaks
Description: The rationale for combining Tr and RHT is based on immune mechanisms induced by local heating of which are independent of the anti-tumor effects of Tr. Recent results demonstrate that an acute inflammation at the site of the heated tumor area and danger signals are responsible for immune reactions against tumor and metastases (Frey 2012). Abscopal effects after local radiation of tumors with response of distant metastases are induced by similar mechanisms like heat stress (Formenti 2013, Golden 2015). The long-term results for soft-tissue sarcoma are consistent with abscopal effects induced by RHT in a randomized trial compared to chemotherapy alone (Issels 2018).

Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: DNA double-strand breaks
Description: The rationale for combining Tr and RHT is based on immune mechanisms induced by local heating of which are independent of the anti-tumor effects of Tr. Recent results demonstrate that an acute inflammation at the site of the heated tumor area and danger signals are responsible for immune reactions against tumor and metastases (Frey 2012). Abscopal effects after local radiation of tumors with response of distant metastases are induced by similar mechanisms like heat stress (Formenti 2013, Golden 2015). The long-term results for soft-tissue sarcoma are consistent with abscopal effects induced by RHT in a randomized trial compared to chemotherapy alone (Issels 2018).
Study: NCT01436422

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: TetraVax-DV Vaccine - Admixture TV003
Description: One subcutaneous injection at Day 0 and Day 180 of a live attenuated recombinant TetraVax-DV vaccine, Admixture TV003 (10\^3 PFU of rDEN1Δ30, 10\^3 PFU of rDEN2/4Δ30(ME), 10\^3 PFU of rDEN3Δ30/31-7164, and 10\^3 PFU of rDEN4Δ30)

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: TetraVax-DV Vaccine - Admixture TV005
Description: One subcutaneous injection at Day 0 and Day 180 of a live attenuated recombinant TetraVax-DV vaccine, Admixture TV005 (10\^3 PFU of rDEN1Δ30, 10\^4 PFU of rDEN2/4Δ30(ME), 10\^3 PFU of rDEN3Δ30/31-7164, and 10\^3 PFU of rDEN4Δ30)

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: One subcutaneous injection at Day 0 and Day 180 of placebo
Study: NCT02113397

Intervention type: DRUG
Intervention: TOBI™ Podhaler™ 112 mg inhaled twice daily

Intervention type: DRUG
Intervention: Colistimethate 75 mg inhaled two times daily
Study: NCT00753740

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IT-101 (12mg/m2/dose)
Description: Patients who satisfy the inclusion/exclusion criteria will receive a blinded infusion of IT-101 (12mg/m2/dose) every other week until disease progression.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IT-101 (15mg/m2/dose)
Description: Patients who satisfy the inclusion/exclusion criteria will receive an infusion of IT-101 (15mg/m2) every other week until disease progression.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: 5% Dextrose (Placebo)
Description: Patients who satisfy the inclusion/exclusion criteria will receive an infusion of placebo every other week until disease progression.
Study: NCT00183417

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive behavior therapy (CBT)
Description: Participants will complete worksheets and group discussion on how to increase positive mood and activity.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Supportive/expressive (S/E) therapy
Description: Participants will be encouraged to express feelings and emotions without advice giving.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Bibliotherapy
Description: Participants will be given a book on how to increase their mood.
Study: NCT03820739

Intervention type: OTHER
Intervention: Follow-up
Description: No investigational vaccine will be administered during this study

Intervention type: OTHER
Intervention: Follow-up
Description: No investigational vaccine will be administered during this study

Intervention type: OTHER
Intervention: Blood sample collection
Description: Blood sampling to assess vaccine-induced immune responses will be conducted only in cohort 1 in a subsample consisting of approximately 102 adults and 165 children (55 from each of the three paediatric age groups that were enrolled in EBOVAC-Salone: 12-17 year olds, 4-11 year olds, and 1-3 year olds).
Study: NCT02984930

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Administration of study drug (esomeprazole, mosapride)
Description: Esomeprazole(Hanxium®) 40 mg once daily and mosapride (Gasmotin®) 5 mg t.i.d for 4 weeks.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Administration of study drug (esomeprazole, placebo tablet)
Description: Esomeprazole(Hanxium®) 40 mg once daily and placebo tablets that are identical to mosapride tablets t.i.d (3 times a day) for 4 weeks.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: upper endoscopy, scintigraphy
Description: After medication(4weeks), subjects will be undergo upper endoscopy and scintigraphy.

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: upper endoscopy, scintigraphy
Description: After medication(4weeks), subjects will be undergo upper endoscopy and scintigraphy.
Study: NCT02756429

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: blood samples
Description: Patients with atrial fibrillation for whom electrophysiology exploration or ablation are programmed; All blood samples will be taken through the exploration catheter. For the peripheral blood sample, blood will be taken at the introduction of the catheter into the femoral vein. Then the blood samples in the coronary sinus and in the left atrium will be made at progressively exploration.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: blood samples
Description: Patients with atrial fibrillation for whom electrophysiology exploration or ablation are programmed; All blood samples will be taken through the exploration catheter. For the peripheral blood sample, blood will be taken at the introduction of the catheter into the femoral vein. Then the blood samples in the coronary sinus and in the left atrium will be made at progressively exploration.
Study: NCT01457352

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SPARC0921

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo0921
Study: NCT01352403

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Roux-en-Y gastric bypass

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Psychotherapy-enhanced lifestyle intervention
Study: NCT01028300

Intervention type: DEVICE
Group type: OTHER
Intervention: ProDisc™-L Total Disc Replacement (TDR)
Description: The design is based on a ball and socket articulation, one surface being metal and the other an ultra-high molecular weight polyethylene (UHMWPE). Three components comprise this modular prosthesis.
Study: NCT02220088

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: TAI of FOLFOX
Description: Retreatment with TAI: administration of Oxaliplatin , fluorouracil, and leucovorin via the tumor feeding arteries

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sorafenib
Description: Accept sorafenib.
Study: NCT03820466

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Aspirin
Description: Once daily application of platelet inhibiting medication

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aspirin
Description: Once daily application of platelet inhibiting medication

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atorvastatin
Description: Once daily application of lipid lowering medication

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Atorvastatin
Description: Once daily application of lipid lowering medication

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo Aspirin
Description: Once daily application of placebo

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Aspirin
Description: Once daily application of placebo

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo Atorvastatin
Description: Once daily application of placebo

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Atorvastatin
Description: Once daily application of placebo
Study: NCT02648880

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exercise program
Description: Individual exercise sessions in this program implement a whole body approach and consist of a 10-min cardiovascular warm-up and 50 minutes of cardiovascular endurance, resistance, and flexibility exercises. Target intensity of exercise will be based on the American College of Sports Medicine recommendations for cancer survivors. Prior to the start of exercise sessions, participants will be questioned on significant changes in symptoms or the presence of new symptoms (such as nausea or fever), which will used to modify the exercise session for that day to allow maximum symptom-limited participation.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Standard Care
Description: The services that participants receive as standard care include their medical care, symptom control, social worker support, and nutrition. These services are provided by their oncology team.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard Care
Description: The services that participants receive as standard care include their medical care, symptom control, social worker support, and nutrition. These services are provided by their oncology team.
Study: NCT05924763

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Biphasic Cartilage Repair Implant (BiCRI)
Description: The Biphasic Cartilage Repair Implant (BiCRI) is a two-phase scaffold composed of poly(lactic-co-glycolic acid) (PLGA) and β-triCalcium phosphate (TCP).
Study: NCT00987805

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Banhasasim-tang
Description: Form : granules Contents : It consists of seven Herbs. It contains Rhizoma Pinelliae, Radix Scutellariae, Zingiberis Rhizoma, Panax ginseng, Glycyrrhiza uralensis Fisch, Zizyphi Fructus and Coptidis Rhizoma Dosage and frequency : 9g per day (three times a day) Route of administration : Oral Administration duration : 42 days in the study

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Corn-starch granules
Description: This placebo has the same form, color, and flavor as experimental intervention.The dosage, frequency and duration is also same as experimental intervention.
Study: NCT01197339

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: resonant voice
Description: A 4-hr resonant voice exercise will be prescribed to subjects following vocal loading.
Study: NCT02385656

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Modafinil
Description: 200mg of modafinil daily for 4 weeks
Study: NCT01197339

Intervention type: BEHAVIORAL
Group type: SHAM_COMPARATOR
Intervention: voice rest
Description: A 4-hr voice rest will be prescribed to subjects following vocal loading.
Study: NCT01762137

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Flow Diversion
Description: Endovascular flow diverter placement

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Coiling
Description: Endovascular coil placement
Study: NCT00577616

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Endovascular repair
Description: Endovascular repair of the asymptomatic aneurysms of the abdominal aorta

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Endovascular repair
Description: Endovascular repair of the asymptomatic aneurysms of the abdominal aorta
Study: NCT03653559

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Home meals
Description: Adult participants with overweight or obesity are asked to consume home meals during 12 weeks.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Healthy meals
Description: Adult participants with overweight or obesity are asked to consume healthy meals during 12 weeks.
Study: NCT02547961

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: HER-2-targeting CAR T Cells infusion
Description: HER-2-targeting CAR t cells infusion in breast cancer
Study: NCT02660138

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Botulinum toxin type A
Description: 600 U intra detrusor injection in two treatment periods (Initial and Retreatment phase) delivered at 30 injection points

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Botulinum toxin type A
Description: 800 U intra detrusor injection in two treatment periods (Initial and Retreatment phase) delivered at 30 injection points

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: AbobotulinumtoxinA Placebo 600 U intra detrusor injection in two treatment periods (Initial and Retreatment phase) delivered at 30 injection points

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: AbobotulinumtoxinA Placebo 800 U intra detrusor injection in two treatment periods (Initial and Retreatment phase) delivered at 30 injection points
Study: NCT01757340

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Weight loss with normal protein and leucine intake
Description: Goal of 8 to 10% weight loss while consuming the recommended daily allowance of protein (i.e, 0.8 grams of protein per kg body weight per day).
Study: NCT01197339

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Breathy voice
Description: A 4-hr breathy voice exercise will be prescribed to subjects following vocal loading.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Relaxation exercise
Description: A 4-hr relaxation exercise will be prescribed to subjects following vocal loading.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Resonant voice and relaxation exercise
Description: A 4-hr resonant voice and relaxation exercise will be prescribed to subjects following vocal loading.